What is the recommended management of cortical venous thrombosis (CVT) during pregnancy, including anticoagulation, imaging, seizure prophylaxis, and delivery planning?

Management of Cortical Venous Thrombosis in Pregnancy

For pregnant women with cortical venous thrombosis (CVT), initiate therapeutic-dose low-molecular-weight heparin (LMWH) immediately and continue throughout pregnancy and for at least 6 weeks postpartum, with MRI/MRV as the preferred diagnostic modality. 1, 2

Anticoagulation Management

Acute Treatment

• Start therapeutic-dose LMWH immediately upon diagnosis rather than unfractionated heparin, as LMWH is safer and more convenient during pregnancy (strong recommendation). 1
• Either once-daily or twice-daily LMWH dosing regimens are acceptable, though twice-daily dosing may be preferred initially for severe presentations like CVT. 1, 3
• Do not routinely monitor anti-factor Xa levels to guide LMWH dosing in most cases. 1
• Full therapeutic anticoagulation with LMWH does not increase the risk of intracranial hemorrhage in CVT patients, even those with parenchymal involvement. 2

Duration of Therapy

• Continue therapeutic LMWH throughout the entire pregnancy without dose reduction. 2, 4
• Extend anticoagulation for a minimum of 6 weeks postpartum, ensuring at least 3-6 months total treatment duration. 4, 3
• For women with parenchymal lesions, thrombophilia, or antiphospholipid syndrome, longer duration may be warranted as these factors predict worse neurologic outcomes. 2

Diagnostic Imaging

Preferred Modality

• Use MRI with magnetic resonance venography (MRV) as the first-line imaging for all pregnant patients with suspected CVT, avoiding CT when possible. 2
• MRI/MRV should be performed for all patients to confirm the diagnosis and assess for parenchymal involvement. 2
• The superior sagittal and transverse sinuses are most commonly affected; look specifically for these locations. 2

Clinical Presentation to Recognize

• Nearly all CVT cases present with signs of elevated intracranial pressure: headache, vomiting with or without nausea, altered consciousness, and papilledema. 2
• Seizures or status epilepticus occur in approximately 40% of cases and may occur with or without concurrent preeclampsia. 2
• CVT risk is highest in the third trimester, though it can occur at any gestational age. 2

Seizure Management

Acute Seizure Control

• Treat seizures aggressively when they occur, as approximately 40% of pregnant CVT patients develop seizures or status epilepticus. 2
• Standard antiepileptic medications can be used; the presence of therapeutic anticoagulation does not contraindicate seizure treatment. 2

Prophylactic Considerations

• While guidelines do not provide specific recommendations for prophylactic antiepileptic therapy in pregnancy-associated CVT, consider it for patients with parenchymal hemorrhage or infarction. 2
• Patients with parenchymal lesions have higher risk of neurologic sequelae and may benefit from closer monitoring. 2

Delivery Planning

Timing of LMWH Discontinuation

• Stop therapeutic-dose LMWH at least 24 hours before planned delivery or neuraxial anesthesia to allow safe epidural/spinal placement. 1, 5
• For scheduled delivery, discontinue LMWH the morning of the day before induction or planned cesarean section. 1
• If spontaneous labor begins while on therapeutic LMWH, neuraxial anesthesia may not be safe until 24 hours after the last dose. 1

Mode of Delivery

• Planned/scheduled delivery is preferred over awaiting spontaneous labor in women receiving therapeutic-dose LMWH, allowing controlled timing of anticoagulation cessation. 1
• The mode of delivery (vaginal vs. cesarean) should be based on obstetric indications, not anticoagulation status. 1

Postpartum Resumption

• Resume therapeutic LMWH once hemostasis is assured postpartum, typically 6-12 hours after vaginal delivery or 12-24 hours after cesarean delivery. 3
• Continue for the full 6-week postpartum period minimum. 1, 4

Critical Pitfalls to Avoid

• Never delay anticoagulation while awaiting imaging confirmation if CVT is strongly suspected clinically; start LMWH immediately unless clear contraindications exist. 1, 6
• Do not use warfarin during pregnancy due to teratogenicity risk; it may only be considered postpartum during breastfeeding. 7, 8
• Avoid relying on clinical symptoms alone to exclude CVT; objective imaging is mandatory. 3
• Do not reduce LMWH to prophylactic doses during pregnancy in confirmed CVT; full therapeutic dosing must be maintained throughout gestation. 2, 4
• Do not withhold anticoagulation due to fear of hemorrhagic transformation; therapeutic LMWH does not increase intracranial bleeding risk even with parenchymal involvement. 2

Special Considerations

Thrombophilia Screening

• Test for antiphospholipid syndrome and inherited thrombophilias, as these predict higher risk of neurologic sequelae and may influence long-term anticoagulation decisions. 2
• Patients with antithrombin deficiency, homozygous Factor V Leiden, or compound heterozygous thrombophilias require extended prophylaxis. 5

Breastfeeding

• LMWH is safe during breastfeeding and should be continued postpartum. 1
• Warfarin may be used postpartum if preferred, with INR target 2.0-3.0. 5